Regulus Therapeutics Inc.

NasdaqCM:RGLS Stock Report

Market Cap: US$617.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Regulus Therapeutics Past Earnings Performance

Past criteria checks 0/6

Regulus Therapeutics's earnings have been declining at an average annual rate of -18.1%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been declining at an average rate of 65.6% per year.

Key information

-18.10%

Earnings growth rate

46.87%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-65.55%
Return on equity-68.85%
Net Marginn/a
Last Earnings Update31 Mar 2025

Recent past performance updates

Recent updates

Analysis Article • Sep 28

Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Sep 12

Regulus surges 15% after Phase 1 data for kidney disease candidate

The shares of clinical-stage biotech Regulus Therapeutics Inc. (NASDAQ:RGLS) climbed ~15% in the pre-market trading Monday after the company announced topline data from its Phase 1 Single-Ascending Dose (SAD) trial for kidney disease candidate RGLS8429. RGLS8429, designed to target Autosomal Dominant Polycystic Kidney Disease (ADPKD), belongs to a drug class known as oligonucleotides. The topline safety and pharmacokinetics data from the study involving healthy volunteers indicated that RGLS8429 was well-tolerated with no serious adverse events, RGLS said. Among 32 patients who received the therapy, there were nine adverse events, out of which only one (sinus infection) was found to be moderate in severity. With the data update from the SAD portion of the study, the company announced the launch of the Phase 1b Multiple Ascending Dose (MAD) study for the candidate, which involves ADPKD patients. The topline data from the first cohort of patients are expected in 1H 2023. Read: Seeking Alpha contributor Bret Jensen takes a deep dive into RGLS with a Hold rating on the stock.
Seeking Alpha • Aug 11

Regulus Therapeutics GAAP loss per share narrows

Regulus Therapeutics press release (NASDAQ:RGLS): Q2 GAAP EPS of -$0.50 (vs. -$0.78 Y/Y). As of Jun. 30, Regulus had $47.5M in cash, cash equivalents and marketable securities.
Analysis Article • Oct 12

Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Aug 03

The Read On Regulus Therapeutics

Today, we take an in-depth look at Regulus Therapeutics. This small cap developmental firm is focused on microRNA therapeutics and has multiple 'shots on goal' in its pipeline. A full investment analysis follows in the paragraphs below.
Analysis Article • Jun 09

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Shareholders of Regulus Therapeutics Inc. ( NASDAQ:RGLS ) will have been dismayed by the negative share price return...
Analysis Article • Mar 13

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Unfortunately for shareholders, when Regulus Therapeutics Inc. ( NASDAQ:RGLS ) reported results for the period to...
Analysis Article • Mar 10

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Regulus Therapeutics Inc. ( NASDAQ:RGLS ) shareholders might be concerned after seeing the share price drop 10% in the...

Revenue & Expenses Breakdown

How Regulus Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:RGLS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 250-48160
31 Dec 240-46150
30 Sep 240-42139
30 Jun 240-35120
31 Mar 240-31100
31 Dec 230-30100
30 Sep 230-291015
30 Jun 230-2890
31 Mar 230-2990
31 Dec 220-28100
30 Sep 220-29100
30 Jun 220-30100
31 Mar 220-29100
31 Dec 210-28100
30 Sep 215-22100
30 Jun 2110-1590
31 Mar 2110-1690
31 Dec 2010-1690
30 Sep 205-1990
30 Jun 200-23100
31 Mar 200-21100
31 Dec 197-19110
30 Sep 197-22120
30 Jun 197-27120
31 Mar 197-36130
31 Dec 180-49130
30 Sep 180-55130
30 Jun 180-60130
31 Mar 180-68130
31 Dec 170-72130
30 Sep 170-77150
30 Jun 170-81170
31 Mar 171-81170
31 Dec 161-82180
30 Sep 1612-69190
30 Jun 1614-63220
31 Mar 1617-62210
31 Dec 1521-56190
30 Sep 1514-71170
30 Jun 1513-67120
31 Mar 1510-58120
31 Dec 148-57120
30 Sep 149-36100
30 Jun 1414-2990

Quality Earnings: RGLS is currently unprofitable.

Growing Profit Margin: RGLS is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: RGLS is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.

Accelerating Growth: Unable to compare RGLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RGLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.7%).

Return on Equity

High ROE: RGLS has a negative Return on Equity (-68.85%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/25 05:50
End of Day Share Price 2025/06/24 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Regulus Therapeutics Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBMO Capital Markets Equity Research
Madhu KumarB. Riley Securities, Inc.
Madhu KumarChardan Capital Markets, LLC